The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOAs) related to nasal delivery of CNS therapeutics. The projects described in FOAs RFA-DA-18-006 and RFA-DA-18-007 are both supported by Small Business Technology Transfer (STTR) program
Both FOAs say that their purpose is to “is to develop a nasal delivery formulation that reliably delivers of a therapeutic (e.g., peptides, antibodies, RNAi, or pharmacotherapeutics), at a physiologically relevant concentration, into the central nervous system (CNS).”
Both also say that “Formulations that incorporate novel technologies such as, co-polymer micelles, viral vectors, and nanoparticles, are particularly encouraged” and note that “The FDA’s Orange Book currently only lists three approved CNS-related nasal sprays. The global market for direct-to-CNS-delivery technologies is reported to grow to $450 million by 2019, and has increased by 50% per year since 2013.”
Applications are due by August 23, 2017, with the earliest start date in April 2018.
Read FOA RFA-DA-18-006
Read FOA RFA-DA-18-007
